Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes

Journal of Clinical Lipidology

Volumn 2, Issue 1, 2008, Pages 19-24

  Guyton, John R ^a   Goldberg, Ronald B ^b   Mazzone, Theodore ^c   Weinstock, Ruth S ^d   Polis, Adam ^e   Rosenberg, Elizabeth ^e   Tershakovec, Andrew M ^e  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Apolipoprotein B A I ratio; Atorvastatin; Diabetes mellitus; Ezetimibe; Lipoprotein ratios; Simvastatin

Indexed keywords

ANTIDIABETIC AGENT; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; EZETIMIBE PLUS SIMVASTATIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYSIS OF VARIANCE; ARTERY WALL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC DIET; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 39149103699     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2007.12.004     Document Type: Article

References (32)

1. Castelli W.P., Abbott R.D., and McNamara P.M. Summary estimates of cholesterol used to predict coronary heart disease. Circulation 67 (1983) 730-734
2. Grover S.A., Coupal L., and Hu X.P. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work?. JAMA 274 (1995) 801-806
3. Natarajan S., Glick H., Criqui M., Horowitz D., Lipsitz S.R., and Kinosian B. Cholesterol measures to identify and treat individuals at risk for coronary heart disease. Am J Prev Med 25 (2003) 50-57
4. Blake G.J., Otvos J.D., Rifai N., and Ridker P.M. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106 (2002) 1930-1937
5. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., and Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001) 2026-2033
6. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952
7. Jiang R., Schulze M.B., Li T., et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 27 (2004) 1991-1997
8. Gotto Jr. A.M., Whitney E., Stein E.A., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101 (2000) 477-484
9. Haffner S.M. Diabetes, hyperlipidemia, and coronary artery disease. Am J Cardiol 83 (1999) 17F-21F
10. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
11. Temelkova-Kurktschiev T., and Hanefeld M. The lipid triad in type 2 diabetes-prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes. Exp Clin Endocrinol Diabetes 112 (2004) 75-79
12. Solano M.P., and Goldberg R.B. Management of dyslipidemia in diabetes. Cardiol Rev 14 (2006) 125-135
13. Goldberg R.B., Guyton J.R., Mazzone T., et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc 81 (2006) 1579-1588
14. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
15. Grundy S.M. Approach to lipoprotein management in 2001 National Cholesterol Guidelines. Am J Cardiol 90 (2002) 11i-21i
16. Grundy S.M. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 106 (2002) 2526-2529
17. Garg R., Vasamreddy C.R., and Blumenthal R.S. Non-high-density lipoprotein cholesterol: why lower is better. Prev Cardiol 8 (2005) 173-177
18. Barter P.J., Ballantyne C.M., Carmena R., et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 259 (2006) 247-258
19. McPherson R., Frohlich J., Fodor G., Genest J., and Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement-recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 22 (2006) 913-927
20. Barter P.J., and Rye K.A. The rationale for using apoA-I as a clinical marker of cardiovascular risk. J Intern Med 259 (2006) 447-454
21. Koro C.E., Bowlin S.J., Stump T.E., Sprecher D.L., and Tierney W.M. The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events. Am Heart J 151 (2006) 755
22. Duvall W.L., Blazing M.A., Saxena S., and Guyton J.R. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy. J Cardiovasc Risk 9 (2002) 339-347
23. Horng Y.C., Wei J.S., Chang R.S., Huang H.S., Huang M.J., and Huang B.Y. Apolipoprotein levels in normolipidemic non-insulin-dependent diabetes mellitus. J Formos Med Assoc 91 (1992) 590-594
24. Oyelola O.O., Ajayi A.A., Babalola R.O., and Stein E.A. Plasma lipids, lipoproteins, and apolipoproteins in Nigerian diabetes mellitus, essential hypertension, and hypertensive-diabetic patients. J Natl Med Assoc 87 (1995) 113-118
25. Habib S.S., Aslam M., Naveed A.K., and Razi M.S. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy. Saudi Med J 27 (2006) 174-180
26. Cannon C.P., Steinberg B.A., Murphy S.A., Mega J.L., and Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48 (2006) 438-445
27. Armitage J., and Bowman L. Cardiovascular outcomes among participants with diabetes in the recent large statin trials. Curr Opin Lipidol 15 (2004) 439-446
28. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
29. Shepherd J., Barter P., Carmena R., et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29 (2006) 1220-1226
30. Sever P.S., Dahlöf B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
31. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
32. Cholesterol Treatment Trialists' Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 (2008) 117-125